COMP <GO>
ELTX vs MREO // 10Y YIELD & FRED MACRO BETA
Elicio Therapeutics Inc. (NASDAQ) VS. Mereo BioPharma Group plc (NASDAQ) • 15-METRIC TALLY: ELTX 1
— MREO 2
■ METRIC PARITY
LAST: $1.75 (-5.40%) • MKT CAP: $47.4M
macro-sensitivity
—
LAST: $0.30 (+1.62%) • MKT CAP: $48.2M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELTX VS. MREO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELTX | MREO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ELTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.0 | 47.0 | -2.00 | MREO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $47.4M | $48.2M | -$763.3K | MREO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELTX REV | MREO REV | ELTX GROSS % | MREO GROSS % | ELTX FCF | MREO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $500.0K | — | — | -$37.0M | -$31.0M |
| FY 2024 | $0 | $0 | — | — | -$37.2M | -$32.8M |
| FY 2023 | $0 | $10.0M | — | — | -$32.7M | -$21.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELTX // BETA —
MREO // BETA —